FindTrial
Sign In

How long do patients live who have diagnosis of a cancerous rumour called sarcoma and who present with disease spread

Prospective analyses of survival of patients with indeterminate lesions and unequivocal metastatic disease at presentation in Bone & Soft tissue sarcoma across all ages of patients presenting to BST DMG, agnostic of the intent of treatment and site of metastasis or burden of disease - METSARC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/066551
Enrollment
200
Registered
2024-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C419- Malignant neoplasm of bone and articular cartilage, unspecified Health Condition 2: C499- Malignant neoplasm of connective and soft tissue, unspecified Health Condition 3: C409- Malignant neoplasm of unspecifiedbones and articular cartilage of limb

Interventions

Intervention1: nil: nil Control Intervention1: nil: nil

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. patient of any age/sex who presents with indeterminate lesions, or unequivocal radiological metastasis (including skip metastases), or biopsy proven synchronous metastatic disease in radiologically equivocal cases, at presentation, stratified for Ewing’s Sarcoma, Osteosarcoma (all subtypes), chondrosarcoma, Soft tissue sarcoma (round cell and NRSTS, including radiation induced sarcoma) irrespective of intent of treatment. 2. Histopathological confirmation of primary sarcoma diagnosis at TMH 3. Imaging review of standard of care staging investigations at TMH or documented radiology consensus at joint clinic appraisals for obvious metastases. 4. Indeterminate lesions based off validated radiologic criteria and consensus in multi-disciplinary joint clinic (subcentimetre lesions, equivocal characteristics, minimal impact, not amenable to biopsy).

Exclusion criteria

Exclusion criteria: 1. Metachronous metastases (after a disease free/treatment free interval) 2. Absence of histopathological review at TMH 3. Absence of imaging review at TMH

Design outcomes

Primary

MeasureTime frame
Primary End point: Overall Survival at 3 years (death due to any cause) Survival in months (from date of diagnosis of metastatic disease to date of death/last patient contact/censored observation at the end of study period)Timepoint: Primary End point: Overall Survival at 3 years (death due to any cause) Survival in months (from date of diagnosis of metastatic disease to date of death/last patient contact/censored observation at the end of study period)—

Secondary

MeasureTime frame
Secondary endpoints: QOL at baseline, during every hospital visit, then 3–6 monthly until end of study as measured by EORTC QLQ30.Timepoint: 2 years—

Countries

India

Contacts

Public ContactPrakash Radhakrishna Nayak

Tata Memorial Hospital

nayakprakash@gmail.com24177000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026